Summary:
A Phase 3, randomized, double-blind, placebo-controlled, ,ulticenter study to assess the efficacy and safety of one investigational medication for 2 weeks, followed by another investigational medication for 4 weeks, versus Placebo in subjects with active mild to moderate Ulcerative Proctitis or Proctosigmoiditis.
Qualified Participants Must:
• Be over 18 years of age
•
If female and of childbearing(reproductive) potential must have a negative serum pregnancy test at screening and agree to use an acceptable method of contraception throughout their participation in the study
•
Have a confirmed diagnosis of Active, Mild to Moderate, ulcerative Proctitis or Proctosigmoiditis
•
Have diagnosis confirmed by Endoscopy
•
Understand the language of the informed consent form, and be capable and willing to sign the informed consent form